Outcome of patients hospitalized for Covid-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France: Results of the ACECoV study

Fundam Clin Pharmacol. 2021 Feb;35(1):192-193. doi: 10.1111/fcp.12637. Epub 2021 Jan 6.

Authors

Joachim Alexandre¹, Jean-Luc Cracowski²

Affiliations

¹ UNICAEN, CHU de Caen Normandie, Service de Pharmacologie, Université de Caen-Normandie, EA 4650, F-14000, CAEN, France.
² Centre Régional de Pharmacovigilance de Grenoble, INSERM, HP2, Univ. Grenoble Alpes, F-38000, Grenoble, France.

PMID: 33290594
DOI: 10.1111/fcp.12637

No abstract available

Publication types

Editorial
Comment

MeSH terms

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
COVID-19*
France
Humans
Hypertension*
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins